Venus Pharma GmbH – Medgate Today

Venus Remedies Granted Market Authorization for Bleomycin 15,000 IU in the United Kingdom

October 26, 2023

7:07 am

Obtaining market authorization for Bleomycin from MHRA is a momentous accomplishment for Venus Pharma GmbH. Venus Remedies holds a total of 15 Market Authorizations (MA) for Bleomycin products across the globe. Venus Remedies is thrilled to announce the achievement of market authorization in the United Kingdom

POST TAGS:

VENUS REMEDIES BAGS APPROVAL TO MARKET MEROPENEM, ITS BLOCKBUSTER GENERIC DRUG, IN SPAIN

June 23, 2023

5:10 am

News Update

admin

The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries Venus Remedies has been the largest exporter of meropenem from India in the last three years Riding on the upcoming

POST TAGS:

Akshansh Chaudhary Global Critical Care Meropenem Saransh Chaudhary Venus Venus Pharma GmbH Venus Remedies

Venus Remedies Granted Market Authorization for Bleomycin 15,000 IU in the United Kingdom

POST TAGS:

VENUS REMEDIES BAGS APPROVAL TO MARKET MEROPENEM, ITS BLOCKBUSTER GENERIC DRUG, IN SPAIN

POST TAGS:

FIND US

ADDRESS

FOLLOW US ON SOCIAL MEDIA